<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513834</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0339</org_study_id>
    <nct_id>NCT04513834</nct_id>
  </id_info>
  <brief_title>Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial</brief_title>
  <acronym>DeprescrIPPDAM</acronym>
  <official_title>Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deprescribing is defined as &quot;the process of withdrawal of an inappropriate medication,&#xD;
      supervised by a health care professional with the goal of managing the polypharmacy and&#xD;
      improving outcomes&quot;. Inappropriate use of proton pump inhibitors (PPI) is associated with&#xD;
      severe adverse drug reactions and a major economic impact. Deprescribing should be considered&#xD;
      when inappropriate prescription of PPI is identified.&#xD;
&#xD;
      DeprescrIPP DAM is a pragmatic trial, population-based, designed in clusters. It wil assess&#xD;
      the efficacy of a multi-faceted intervention (an educational outreach visit to general&#xD;
      practitioners associated with the sending of patient education material to their patients) to&#xD;
      deprescribe PPI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2022</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PPI deprescribing</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients achieving a 50% decrease in their reimbursement of PPI (Defined Daily Dose (DDD)/year) at the end of the intervention compared to baseline (estimated with reimbursement databases)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of patients engaging in the deprescription process</measure>
    <time_frame>12 months</time_frame>
    <description>Sex, age, long-term illness, universal health insurance, complementary health insurance, medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25000</enrollment>
  <condition>Proton Pump Inhibitors</condition>
  <condition>Deprescription</condition>
  <arm_group>
    <arm_group_label>Multi-faceted intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational outreach visit to GPs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Neither the patients nor their GP will receive any information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GP will receive the educational outreach visit by a DAM (healthcare representative).</intervention_name>
    <description>GP will receive the educational outreach visit by a DAM (healthcare representative).</description>
    <arm_group_label>Educational outreach visit to GPs</arm_group_label>
    <arm_group_label>Multi-faceted intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient education material on PPI deprescribing will be sent to the patients</intervention_name>
    <description>Patient education material on PPI deprescribing will be sent to the patients</description>
    <arm_group_label>Multi-faceted intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General practitioners (GP)&#xD;
&#xD;
             • All GP settled in the 3 French departments Maine-et-Loire, Mayenne, Sarthe having&#xD;
             seen more than 100 different patients in the year before baseline, will be eligible.&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  Aged more than 18 years old&#xD;
&#xD;
               -  Affiliated to the French health insurance CPAM&#xD;
&#xD;
               -  Treated with PPI&gt; 300DDD/year in the year before baseline (estimated with&#xD;
                  reimbursement databases).&#xD;
&#xD;
               -  Whose GP is included in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General practitioners (GPs) :&#xD;
&#xD;
             • Participation refusal&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  Participation refusal&#xD;
&#xD;
               -  Patients aged &gt;65 or with corticosteroids/anticoagulants and NSAIDs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pascal FOURNIER, Doctor</last_name>
    <phone>02.40.41.28.28</phone>
    <email>jean-pascal.fournier@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jérôme NGUYEN, Doctor</last_name>
    <phone>02.40.41.28.28</phone>
    <email>jerome.nguyen-soenen@univ-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Pascal FOURNIER, Doctor</last_name>
      <phone>02.40.41.28.28</phone>
      <email>jean-pascal.fournier@univ-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérôme NGUYEN, Doctor</last_name>
      <phone>02.40.41.28.28</phone>
      <email>jerome.nguyen-soenen@univ-nantes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proton pump inhibitors</keyword>
  <keyword>Deprescription</keyword>
  <keyword>Multi-faceted intervention</keyword>
  <keyword>Patient-centered</keyword>
  <keyword>Primary health care</keyword>
  <keyword>Pharmacoepidemiology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

